Literature DB >> 30871851

WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance.

Hiroshi Inoue1, Shinichiro Uchiyama2, Hirotsugu Atarashi3, Ken Okumura4, Yukihiro Koretsune5, Masahiro Yasaka6, Takeshi Yamashita7, Atsushi Taniguchi8, Taku Fukaya8.   

Abstract

The Publisher regrets that this article is an accidental duplication of an article that has already been published in Journal of Cardiology, 73/6 (2018) 507–514, https://doi.org/10.1016/j.jjcc.2018.12.013. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Atrial fibrillation; Dabigatran; Outcomes; Post-marketing surveillance; Safety

Year:  2019        PMID： 30871851     DOI： 10.1016/j.jjcc.2019.02.008

Source DB:  PubMed          Journal:  J Cardiol        ISSN： 0914-5087            Impact factor:   3.159


  1 in total

1.  Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.

Authors:  Akiko Harada; Ippei Ikushima; Miwa Haranaka; Aki Yanagihara; Daisuke Nakayama
Journal:  Am J Cardiovasc Drugs       Date:  2020-06       Impact factor: 3.571
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.